United Therapeutics Corporation $UTHR Shares Acquired by FORA Capital LLC

Key Points

• FORA Capital LLC increased its stake in United Therapeutics Corporation by 80.4%, acquiring an additional 4,318 shares, bringing its total holdings to 9,689 shares valued at approximately $2.99 million.
• United Therapeutics reported a net margin of 40.36% in its last earnings release, with a revenue of $798.60 million, reflecting an 11.7% year-over-year growth.
• Major analysts have set a consensus rating of "Moderate Buy" for United Therapeutics, with an average target price of $382.00 despite some reducing their target prices.

FORA Capital LLC increased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 80.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,689 shares of the biotechnology company's stock after acquiring an additional 4,318 shares during the period. FORA Capital LLC's holdings in United Therapeutics were worth $2,987,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of UTHR. Stifel Financial Corp lifted its stake in United Therapeutics by 12.0% during the 4th quarter. Stifel Financial Corp now owns 7,744 shares of the biotechnology company's stock worth $2,732,000 after acquiring an additional 831 shares in the last quarter. Tudor Investment Corp ET AL raised its position in United Therapeutics by 139.5% in the 4th quarter. Tudor Investment Corp ET AL now owns 22,387 shares of the biotechnology company's stock valued at $7,899,000 after purchasing an additional 13,041 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in United Therapeutics by 26.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 123,317 shares of the biotechnology company's stock valued at $43,511,000 after purchasing an additional 25,848 shares in the last quarter. Northern Trust Corp raised its position in United Therapeutics by 29.1% in the 4th quarter. Northern Trust Corp now owns 488,854 shares of the biotechnology company's stock valued at $172,487,000 after purchasing an additional 110,298 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its position in United Therapeutics by 768.8% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 2,702 shares of the biotechnology company's stock valued at $953,000 after purchasing an additional 2,391 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Price Performance

Shares of UTHR stock traded down $2.48 during midday trading on Monday, hitting $304.76. The company had a trading volume of 418,774 shares, compared to its average volume of 695,087. The company's 50 day simple moving average is $299.03 and its 200 day simple moving average is $304.77. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a market cap of $13.75 billion, a price-to-earnings ratio of 11.90, a PEG ratio of 4.62 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter last year, the business posted $5.85 earnings per share. The company's revenue for the quarter was up 11.7% compared to the same quarter last year. Analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on UTHR shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of United Therapeutics in a research report on Thursday, August 14th. JPMorgan Chase & Co. reduced their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Morgan Stanley reduced their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. HC Wainwright set a $400.00 price target on United Therapeutics and gave the company a "buy" rating in a research report on Thursday, July 31st. Finally, Bank of America reduced their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. Nine investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $382.00.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at approximately $2,641,353.66. This trade represents a 59.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the sale, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 81,681 shares of company stock valued at $24,537,839. Company insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.